SAHPRA Approves Pfizer’s Paxlovid COVID-19 Treatment
SAHPRA announced the registration of Paxlovid COVID-19 treatment, an anti-viral medicine manufactured by Pfizer, to treat COVID-19. This is a 5-day oral treatment for mild to moderate COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.
International sources provide guidelines regarding prescribing in liver and kidney disease as well as possible drug interactions including statin therapy, anticoagulation and some hormonal birth control treatments.
Recent Posts
Genotype ECG Prediction
Bridging Genotype ECG Prediction to Enhanced Cardiovascular Risk Assessment
Genotype ECG prediction advancements, exemplified by the CapECG model, enable direct mapping of genetic data to electrocardiogram ...
Glofitamab Cost-Effectiveness: Conditional Reimbursement Insights for DLBCL Treatment
Glofitamab Cost-Effectiveness in R/R DLBCL Reimbursement
Glofitamab cost-effectiveness analysis by Zorginstituut Nederland supports conditional inclusion of glofitamab (Columvi®) with gemcitabine and oxaliplatin (Glofit-GemOx)...
NICE Endorses Pegzilarginase for Treating Arginase Deficiency
NICE Backs Pegzilarginase for Arginase Deficiency
The National Institute for Health and Care Excellence (NICE) final draft guidance recommends pegzilarginase arginase deficiency treatment (Loargys, Immedica) as an option for people ...